{
    "clinical_study": {
        "@rank": "72144", 
        "acronym": "ViDImmun", 
        "arm_group": [
            {
                "arm_group_label": "intramuscular 100.000 I.U. vitamin D3", 
                "arm_group_type": "Active Comparator", 
                "description": "intramuscular 100.000 I.U. vitamin D3"
            }, 
            {
                "arm_group_label": "intramuscular placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "intramuscular 0.9% sodium chloride"
            }, 
            {
                "arm_group_label": "subcutaneous 100.000 I.U. vitamin D3", 
                "arm_group_type": "Active Comparator", 
                "description": "subcutaneous 100.000 I.U. vitamin D3"
            }, 
            {
                "arm_group_label": "subcutaneous placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "subcutaneous 0.9% sodium chloride"
            }
        ], 
        "brief_summary": {
            "textblock": "Vitamin D receptors are expressed in activated different immune cells. It is not known,\n      which immune cell type is targeted by exogenous vitamin D. Here, vitamin D-deficient\n      individuals will receive once 100.000 I.U. vitamin D3 either intramuscular or subcutaneous\n      in a double-blind placebo controlled setting. Immune cells will be monitored from the blood\n      over time."
        }, 
        "brief_title": "Immunologic Action of a Single Dose Cholecalciferol", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Vitamin D Deficiency", 
        "condition_browse": {
            "mesh_term": "Vitamin D Deficiency"
        }, 
        "detailed_description": {
            "textblock": "Vitamin D-deficient individuals will receive once\n\n        -  double-blind, placebo controlled 100.000 I.U.vitamin D3\n\n        -  intramuscular or subcutaneous\n\n      Blood will be taken over time and\n\n        -  immune cells (T cells, B cells, myeloid antigen presenting cells) are characterized by\n           flow-cytometry\n\n        -  vitamin D-metabolites will be monitored"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  informed consent\n\n          -  18-60 yrs\n\n          -  25-hydroxyvitamin D serum below 50 nmol/L\n\n          -  women only: effective contraception\n\n        Exclusion Criteria:\n\n          -  25-hydroxyvitamin D serum above 50 nmol/L\n\n          -  body-mass index <18 or >30 kg per m2\n\n          -  planned UV-exposure (UV-index > 5)\n\n          -  hypersensitivity to vitamin D\n\n          -  history of hypercalcemia, kidney stones, kidney insufficiency, sarcoidosis,\n             pseudohyperparathyroidism concomitant vitamin A- and/or vitamin D treatment\n\n          -  treatment with immunosuppressants, immunomodulators, phenytoin, barbiturate,\n             thiazide-diuretics, glycosides\n\n          -  immobile patients\n\n          -  out of normal range on screening visit (calcium,phosphate,creatinin,hematology)\n\n          -  psychiatric hospitalization\n\n          -  pregnancy / breast-feeding\n\n          -  dependency / relationship on sponsor\n\n          -  concomitant participation in other clinical trials (30 days before)\n\n          -  drug or alcohol abuse\n\n          -  lack of compliance"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01845142", 
            "org_study_id": "ViDImmun", 
            "secondary_id": "2012-003217-33"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "intramuscular 100.000 I.U. vitamin D3", 
                    "subcutaneous 100.000 I.U. vitamin D3"
                ], 
                "intervention_name": "single administration of 100.000 I.U. vitamin D", 
                "intervention_type": "Drug", 
                "other_name": "cholecalciferol"
            }, 
            {
                "arm_group_label": [
                    "intramuscular placebo", 
                    "subcutaneous placebo"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cholecalciferol", 
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "vitamin D", 
            "vitamin D deficiency", 
            "immune cells", 
            "pharmacokinetic", 
            "< 50 nmol/L 25(OH)D serum concentration"
        ], 
        "lastchanged_date": "March 17, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany", 
                    "zip": "10117"
                }, 
                "name": "Dpt of Dermatology and Allergology, Charit\u00e9 University Medicine Berlin"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "4", 
        "official_title": "Immunologic Functions of a Single Dose of 100.000 I.U. Cholecalciferol (Vitamin D3)", 
        "overall_official": {
            "affiliation": "Charite University, Berlin, Germany", 
            "last_name": "Margitta Worm, Prof", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Peripheral B cells will be isolated before, after 1 week, 1 month and 3 months after vitamin D administration and characterized by flow-cytometry. Vitamin D-responsive B cells will be quantified before and 1 week, 1 month and 3 months after vitamin D administration.", 
            "measure": "Change in the numbers of vitamin D-responsive B cells after vitamin D administration.", 
            "safety_issue": "No", 
            "time_frame": "up to 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01845142"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Charite University, Berlin, Germany", 
            "investigator_full_name": "Margitta Worm", 
            "investigator_title": "Prof. Dr. med.", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "peripheral blood mononuclear cells will be isolated before, after 1 week, 1 month and 3 months after vitamin D administration and monocytes will be characterized phenotypically by flow-cytometry.", 
                "measure": "Characterize vitamin D-responding myeloid immune cells", 
                "safety_issue": "No", 
                "time_frame": "up to 3 months"
            }, 
            {
                "description": "The humoral immunoglobulin response against selected endogenous viruses (anti-virus-specific-Ig) over time will be determined before and 3 months after vitamin D administration.", 
                "measure": "Impact of vitamin D on specific humoral memory", 
                "safety_issue": "No", 
                "time_frame": "up to 3 months"
            }, 
            {
                "description": "Vitamin D-metabolites including 25-hydroxyvitamin D will be determined up to 3 months after administration of a single dose-vitamin D.", 
                "measure": "Vitamin D pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "up to 3 months"
            }, 
            {
                "description": "peripheral T cells will be isolated before, after 1 week, 1 month and 3 months after vitamin D administration and characterized by flow-cytometry according to functional subpopulations.", 
                "measure": "Characterize vitamin D-responsive T cells", 
                "safety_issue": "No", 
                "time_frame": "up to 3 months"
            }
        ], 
        "source": "Charite University, Berlin, Germany", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Margitta Worm", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}